

Product Data Sheet

Product Name: CDK8-IN-12

Cat. No.: GC73183

Chemical Properties

Cas. No. 2613307-67-6


Formula $C_{21}H_{20}ClN_3O_2$ M.Wt 381.86

Solubility DMSO : 66.67 mg/mL (174.59 mM; Storage -20°C
Need ultrasonic)

General tips For obtaining a higher solubility , please warm the tube at 37 °C and shake it in the ultrasonic bath for a while. Stock solution can be stored below -20°C for several months.

Shipping Condition Evaluation sample solution : ship with blue ice All other available size: ship with RT , or blue ice upon request.

Structure



Background

CDK8-IN-12 is an orally active, potent CDK8 inhibitor with a K_i of 14 nM. CDK8-IN-12 has off-target kinase inhibition on GSK-3 α , GSK-3 β , PCK- θ with K_i s of 13 nM, 4 nM, 109 nM, respectively. CDK8-IN-12 shows potent anti-proliferative effects selectively on MV4-11 cell. CDK8-IN-12 is an anti-cancer agent.

CDK8-IN-12 (compound 38) selectively inhibits the proliferation of MV4-11 acute myeloid leukaemia

Caution: Product has not been fully validated for medical applications. For research use only.

Tel: (909) 407-4943 Fax: (626) 353-8530 E-mail: tech@glpbio.com

Address: 10292 Central Ave. #205, Montclair, CA, USA

Product Data Sheet

cells with a GI₅₀ of 0.36 μ M[1]. CDK8-IN-12 (0.36, 0.72 μ M; 2 hours) significantly reduces the phosphorylation of serine 727 on STAT1[1].

CDK8-IN-12 (compound 38; IV; 5 mg/kg for rat and 2 mg/kg for mouse) has a T_{1/2} of 0.9 hours and 0.34 hours for rat and mouse, respectively[1]. Pharmacokinetic Parameters of CDK8-IN-12 [1].

References:

[1]. Mingfeng Yu, et al. Potent and orally bioavailable CDK8 inhibitors: Design, synthesis, structure-activity relationship analysis and biological evaluation. Eur J Med Chem. 2021 Mar 15;214:113248.

Caution: Product has not been fully validated for medical applications. For research use only.

Tel: (909) 407-4943 Fax: (626) 353-8530 E-mail: tech@glpbio.com

Address: 10292 Central Ave. #205, Montclair, CA, USA